IGEN BIOLAB is a research company developing, among others, novel therapeutical formulations for treatment and prevention of diseases related to the human microbiome dysfunction.


IGEN BIOLAB is proprietary of several different protein profiles, peptides and amino acids of microbial origin used as active ingredient in a pharmaceutical formulation capable to induce an antitumor response, for the treatment of advanced metastatic solid tumors.

So far a multicenter clinical trial is ongoing. Clinical trial in Lung Cancer patients in late stage, phase II, comparative, randomized. Patients are under best standard of care plus/minus IGEN BIOLAB formulation with primary objective of Quality of Life and overall survival. Clinical and radiological response, nutritional/biochemical markers and microbiota variations will also be measured.

Other developments

We are also seeking to develop a new therapeutic and prevention clinical studies including:

  • Autism Spectrum Disorders
  • Rheumatoid Arthritis
  • Antiaging
  • Skin health
  • Woman´s health
  • Oral health
  • Mood
  • Intestinal Bowel Disease
  • Age-related macular degeneration (AMD)